Skip to main content

Table 1 Characteristics of Cardiometabolic Drug Clinical Trials in China

From: The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021

Classification

Frequency(%)

Status

 

Proceeding

851 (34.5%)

Completed

1529 (62.0%)

Suspended

20 (0.8%)

Terminated

66 (2.7%)

Trials Phase

 

Phase IV

26 (1.1%)

Phase III

278 (11.3%)

Phase II

169 (6.9%)

Phase I

555 (22.5%)

Bioequivalence

1438 (58.3%)

Type of drugs

 

Chemical Drug

2079 (84.3%)

Biological Product

209 (8.5%)

TCM Compound

97 (3.9%)

Ingredient of Natural Drug

60 (2.4%)

NA

21 (0.9%)

Design

 

Single-arm

100 (4.1%)

Crossover

1663 (67.4%)

Parallel-group

698 (28.3%)

Factorial design

5 (0.2%)

Randomization

 

Randomization

2353 (95.4%)

Non-randomization

113 (4.6%)

Blinding

 

Open-label

1867 (75.7%)

Single-blind

35 (1.4%)

Double-blind

564 (22.9%)

Coverage

 

Domestic

2401 (97.4%)

International Multi-center

65 (2.6%)

  1. Abbreviations: NA. Not applicable